Archivos de bronconeumologia · 2003
[Non-small cell lung cancer. Survival after radiotherapy and prognostic factors].
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jaén Olasolo J, Alonso Redondo E, León Jiménez A, Rueda Ramos A
Аннотация
OBJECTIVE: To analyze the results of radiotherapy for non-small cell lung cancer and identify the clinical and therapeutic variables that might influence prognosis.
PATIENTS AND METHODS: In a population base of 109 patients, 87 met the enrollment criteria. The patients received thoracic radiotherapy over the macroscopic tumor volume and lymph drainage areas, using conventional fractions. Systemic cytostatic therapy was also given to 61% of the patients.
RESULTS: Staging was as follows: 33% (28/87) I and II, 20% (18/87) IIIA and 47% (41/87) IIIB. The mean radiotherapy dose was 66.7 Gy (95% CI, 65-67). Full clinical remission was achieved by 22% (18/87), half of whom later suffered recurrences. Partial remission was achieved by 26% (21/87). No response was observed in 52% (42/87). Statistically significant differences in actuarial survival rates were found for staging and tumor response. Mean survival for stages I and II was 29 months (95% CI, 19-39), for IIIA it was 22 (95% CI, 16-28) months, and for IIIB 16 months (95% CI, 12-20). The most common complications were cutaneous, esophageal and pulmonary, with a low incidence of grade 3 toxicity (less than 3%) and absence of grade 4.
CONCLUSIONS: No differences in survival were observed for age, tumor location or histological type. Local control of the disease decisively influenced patient survival.
PATIENTS AND METHODS: In a population base of 109 patients, 87 met the enrollment criteria. The patients received thoracic radiotherapy over the macroscopic tumor volume and lymph drainage areas, using conventional fractions. Systemic cytostatic therapy was also given to 61% of the patients.
RESULTS: Staging was as follows: 33% (28/87) I and II, 20% (18/87) IIIA and 47% (41/87) IIIB. The mean radiotherapy dose was 66.7 Gy (95% CI, 65-67). Full clinical remission was achieved by 22% (18/87), half of whom later suffered recurrences. Partial remission was achieved by 26% (21/87). No response was observed in 52% (42/87). Statistically significant differences in actuarial survival rates were found for staging and tumor response. Mean survival for stages I and II was 29 months (95% CI, 19-39), for IIIA it was 22 (95% CI, 16-28) months, and for IIIB 16 months (95% CI, 12-20). The most common complications were cutaneous, esophageal and pulmonary, with a low incidence of grade 3 toxicity (less than 3%) and absence of grade 4.
CONCLUSIONS: No differences in survival were observed for age, tumor location or histological type. Local control of the disease decisively influenced patient survival.
Предметные рубрики MeSH
Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungCombined Modality TherapyDose Fractionation, RadiationEsophagusHumansLarynxLife TablesLung NeoplasmsLymphatic IrradiationNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingProportional Hazards ModelsRadiation InjuriesRadiodermatitisRadiotherapyRadiotherapy DosageSpainStomachSurvival AnalysisSurvival RateTreatment Outcome